Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard T Silver

Showing results (31-40 of 87) with videos related to

Pageof 9
Sort By:
Blood Advances|March 20, 2024
Cytoreductive therapy in younger adults with polycythemia vera: a meta-analysis of safety and outcomesReem S Chamseddine, Oleksandr Savenkov, Shehroz Rana, et al.
Leukemia Research|July 24, 2010
JAK2(V617F) allele burden in polycythemia vera correlates with grade of myelofibrosis, but is not substantially affected by therapyRichard T Silver, Katherine Vandris, Y Lynn Wang, et al.
Clinical Immunology (Orlando, Fla.)|November 23, 2006
Novel tumor antigens elicit anti-tumor humoral immune reactions in a subset of patients with polycythemia veraZeyu Xiong, Yan Yan, Enli Liu, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 26, 2006
A study of a reduced-intensity conditioning regimen followed by allogeneic stem cell transplantation for patients with hematologic malignancies using Campath-1H as part of a graft-versus-host disease strategyTsiporah Shore, John Harpel, Michael W Schuster, et al.
Haematologica|November 22, 2011
Decrease in JAK2 V617F allele burden is not a prerequisite to clinical response in patients with polycythemia veraEmil Kuriakose, Katherine Vandris, Y Lynn Wang, et al.
Blood|April 15, 2025
DNMT3A mutations are unlikely to affect interferon alfa treatment outcomes in patients with polycythemia veraGhaith Abu-Zeinah, Katie Erdos, Neville Lee, et al.
American Journal of Physiology. Heart and Circulatory Physiology|January 24, 2012
In vivo two-photon excited fluorescence microscopy reveals cardiac- and respiration-dependent pulsatile blood flow in cortical blood vessels in miceThom P Santisakultarm, Nathan R Cornelius, Nozomi Nishimura, et al.
Leukemia|March 3, 2021
Interferon-alpha for treating polycythemia vera yields improved myelofibrosis-free and overall survivalGhaith Abu-Zeinah, Spencer Krichevsky, Tatiana Cruz, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 20, 2006
An unconventional antigen translated by a novel internal ribosome entry site elicits antitumor humoral immune reactionsZeyu Xiong, Enli Liu, Yan Yan, et al.
Clinical Case Reports|May 3, 2021
Response to pegylated interferon in a COVID-19-positive elderly woman with primary myelofibrosis treated with ruxolitinibArthur E Frankel, Renuka Reddy, Kayla R DeSuza, et al.
Pageof 9

Showing results (31-40 of 87) with videos related to

Sort By:
Pageof 9
Blood Advances|March 20, 2024
Cytoreductive therapy in younger adults with polycythemia vera: a meta-analysis of safety and outcomesReem S Chamseddine, Oleksandr Savenkov, Shehroz Rana, et al.
Leukemia Research|July 24, 2010
JAK2(V617F) allele burden in polycythemia vera correlates with grade of myelofibrosis, but is not substantially affected by therapyRichard T Silver, Katherine Vandris, Y Lynn Wang, et al.
Clinical Immunology (Orlando, Fla.)|November 23, 2006
Novel tumor antigens elicit anti-tumor humoral immune reactions in a subset of patients with polycythemia veraZeyu Xiong, Yan Yan, Enli Liu, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 26, 2006
A study of a reduced-intensity conditioning regimen followed by allogeneic stem cell transplantation for patients with hematologic malignancies using Campath-1H as part of a graft-versus-host disease strategyTsiporah Shore, John Harpel, Michael W Schuster, et al.
Haematologica|November 22, 2011
Decrease in JAK2 V617F allele burden is not a prerequisite to clinical response in patients with polycythemia veraEmil Kuriakose, Katherine Vandris, Y Lynn Wang, et al.
Blood|April 15, 2025
DNMT3A mutations are unlikely to affect interferon alfa treatment outcomes in patients with polycythemia veraGhaith Abu-Zeinah, Katie Erdos, Neville Lee, et al.
American Journal of Physiology. Heart and Circulatory Physiology|January 24, 2012
In vivo two-photon excited fluorescence microscopy reveals cardiac- and respiration-dependent pulsatile blood flow in cortical blood vessels in miceThom P Santisakultarm, Nathan R Cornelius, Nozomi Nishimura, et al.
Leukemia|March 3, 2021
Interferon-alpha for treating polycythemia vera yields improved myelofibrosis-free and overall survivalGhaith Abu-Zeinah, Spencer Krichevsky, Tatiana Cruz, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 20, 2006
An unconventional antigen translated by a novel internal ribosome entry site elicits antitumor humoral immune reactionsZeyu Xiong, Enli Liu, Yan Yan, et al.
Clinical Case Reports|May 3, 2021
Response to pegylated interferon in a COVID-19-positive elderly woman with primary myelofibrosis treated with ruxolitinibArthur E Frankel, Renuka Reddy, Kayla R DeSuza, et al.
Pageof 9